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Abstract
A history of preterm birth (PTB) may be an important lifetime risk factor for cardiovascular 
disease (CVD) in women. We identified all peer-reviewed journal articles that met study criteria 
(English language, human studies, female, and adults ≥19 years old), that were found in the 
PubMed/MEDLINE databases, and that were published between Jan. 1, 1995, and Sept. 17, 2012. 
We summarized 10 studies that assessed the association between having a history of PTB and 
subsequent CVD morbidity or death. Compared with women who had term deliveries, women 
with any history of PTB had increased risk of CVD morbidity (variously defined; adjusted hazard 
ratio [aHR] ranged from 1.2e2.9; 2 studies), ischemic heart disease (aHR, 1.3e2.1; 3 studies), 
stroke (aHR, 1.7; 1 study), and atherosclerosis (aHR, 4.1; 1 study). Four of 5 studies that 
examined death showed that women with a history of PTB have twice the risk of CVD death 
compared with women who had term births. Two studies reported statistically significant higher 
risk of CVD—rerelated morbidity and death outcomes (variously defined) among women with —
2 pregnancies that ended in PTBs compared with women who had at least 2 births but which 
ended in only 1 PTB. Future research is needed to understand the potential impact of enhanced 
monitoring of CVD risk factors in women with a history of PTB on risk of future CVD risk.
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Preterm birth (PTB), defined as delivery of an infant at <37 weeks’ gestation, is the leading 
cause of long-term neurologic disabilities in children and the most common cause of infant 
death.1 PTB not only poses risks for the child, but also it may identify women with elevated 
lifetime risks for cardiovascular disease (CVD).2
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In 2011, for the first time the American Heart Association identified 3 pregnancy 
complications (preeclampsia, gestational diabetes mellitus, and pregnancy-induced 
hypertension) as risk factors for CVD and 2 adverse birth outcomes (PTB and delivery of a 
small-for-gestational age infant) as possible risk factors for CVD. 2 CVD typically refers to 
a host of diseases that affect the cardiovascular system and includes atherosclerosis, 
hypertension, coronary heart disease, stroke, heart failure and other conditions. CVD is the 
leading cause of death among women overall and the third leading cause of death among 
women 18-44 years old.3,4 Several systematic reviews have examined associations of 
pregnancy complications and future CVD,5-8 but none have provided an in-depth review of 
the studies that investigated the risk of CVD in mothers with a history of PTB. Some 
proportion of PTBs is caused by hypertension (with and without preeclampsia), infection, 
congenital anomalies, diabetes mellitus, prenatal smoking, and placental abnormalities, but 
the cause of PTB remains unknown in most cases.9 It is plausible that similar alterations in 
inflammatory mediators and immune function might be acting in the pathogenesis of both 
CVD and PTB.10,11 Assessment of the current evidence of the association between PTB and 
future CVD may identify a group of women who possibly could benefit from enhanced 
clinical screening and monitoring.
The aim of this systematic review was to summarize the evidence that is related to PTB and 
subsequent CVD in the mother.
Methods
We used a multistage search strategy to conduct a systematic review of the literature to 
address whether having a PTB is associated with increased risk of future CVD morbidity or 
death. Three investigators (C.L.R., Y.H., P.M.D.) developed the electronic search strategies 
using a combination of free text terms and controlled vocabulary concepts that were derived 
from PubMed’s “All Field” searches and “Medical Subject Headings” and “Title/Abstract” 
field (Table 1). Additional filters that were applied to the searches included limiting the 
searches to English language, human studies, female, and adults who were ≥19 years old and 
to articles that were published from Jan. 1, 1995—Sept. 17, 2012. A 2000 Lancet article 
claimed that no previous studies had examined the association between PTB and 
cardiovascular death,12 and we found no relevant articles before 2000. For the systematic 
review search, the additional filters “Meta-analysis” and “Review” were applied. First, we 
searched the PubMed/MEDLINE and Cochrane Library databases to identify relevant 
systematic reviews or metaanalyses. Next, we searched PubMed/MEDLINE for relevant 
peer-reviewed individual studies.
Data collection entailed study selection and data extraction. Two researchers (C.L.R., Y.H.) 
examined the abstracts with titles that appeared to be relevant and selected all articles that 
examined the association between PTB and future CVD morbidity and/or death in the 
mother. We used researcher agreement to reconcile questions about eligibility. Finally, we 
reviewed reference lists of selected articles to identify any missed articles. We did not search 
unpublished or gray literatures. We considered all study designs. Data abstraction was 
performed by 1 investigator (Y.H.) with Table 2 and was verified by another (C.L.R.).
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We used the Community Guide’s methods and a structured tool to assess the quality of bias 
in individual studies because this tool offered flexibility in the evaluation of articles with 
different study designs (available at: http://www. thecommunityguide.org/library/ajpm 
355_d.pdf).13 This method evaluates validity threats by assessing points for each of 6 
categories: study description (1), sampling (1), measurement (2), data analysis (1), 
interpretation of results (3), and other (ie, limitations not identified in the other 5 categories; 
1). Pairs of investigators (Y.H/C.L.R., Y.H/P.M.D., C.L.R/P.M.D.) independently assessed 
the quality of studies by summing the number of possible flaws and categorizing the study 
accordingly: good (0-1 flaws), fair (2-4), or poor (>4). Differences between independent 
assessments were discussed by 3 investigators (Y.H., C.L.R., P.M.D.) and were resolved by 
consensus. This study was exempt from institutional review board approval because it did 
not involve human subjects.
Results
We identified 185 possible titles of systematic reviews or metaanalyses in PubMed/
MEDLINE, but none of the articles focused on the association between PTB and future 
CVD in the mother. Additionally, we found no relevant reviews in the Cochrane library. The 
initial search for individual studies generated 4828 articles. Many reports were deemed not 
relevant based on title (n = 4432). We identified 10 of the remaining 396 abstracts (2.5%) 
that addressed PTB as a primary exposure for CVD-related outcomes (Figure 1).
Study designs and samples
Table 2 describes exposures, outcomes, and other individual study details in ascending 
chronologic order of publication date. Study designs included case-control (n = 1), cohort (n 
= 8), and cross sectional (n = 1). Study populations were from Denmark (3), Finland (1), 
France (1), Scotland (3), Sweden (1), and the United States (1). Follow-up time from 
delivery to onset of morbidity or death ranged from 12-35 years (Table 3). All but 1 study 
omitted details about the racial composition of their study samples, but most were conducted 
in countries with predominantly white populations.
Exposure
Definitions and sources of PTB varied among the studies (Tables 2 and 4). Most came from 
registries that relied on International Classification of Diseases codes (n = 7)14-20 or medical 
records systems (n = 1)12; 2 studies relied on validated self-report histories among women 
5521 or 8022 years old (on average). Some studies restricted their study population to women 
who gave birth to babies at 24 weeks’ gestation at least16,19,20; some studies used 20 weeks’ 
gestation,18 and other studies had no minimum number of weeks’ gestation.12,14,15,17,21,22 
All but one study used 36 weeks’ gestation to define the upper gestation limit of preterm; 
Nardi et al21 defined PTB as ≤8 months’ gestation. In the 8 studies that used vital records or 
birth registries, gestational age was based on last menstrual period,12,15 estimated date of 
delivery,19,20 or a combination of last menstrual period and ultrasound dating14,17,18; 1 
study did not specify how gestational age was determined.16
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Outcomes
Outcomes that were examined were CVD morbidity (n = 3),15,18,22 CVD death (n = 
5),12,15-17,20 and either CVD hospitalization or death (as a single outcome; n = 5)14,16,19-21 
(Tables 3 and 4). Morbidity outcomes included CVD,15,22 ischemic heart disease (IHD; 
which is the same as coronary heart disease),15,18 stroke,15 and atherosclerosis.15 Death 
outcomes included CVD or IHD death. The definitions of outcomes are shown in Table 4. 
CVD definitions varied from broadly defined CVD (ie, any CVD, atherosclerosis, 
hypertensive disease, IHD stroke, myocardial diseases stroke, thromboembolic diseases, and 
type 2 diabetes mellitus)15,17 to consideration of few major CVD categories: IHD, stroke, 
and peripheral vascular disease22 or IHD, stroke, and heart failure.14 Definition of IHD 
varied from inclusion of all IHD (acute myocardial infarction, other acute and subacute 
forms of IHD, old myocardial infarction, angina pectoris, or other forms of chronic 
IHD)12,14,16,18 to the consideration of myocardial infarction with unstable angina only.14 All 
studies used vital records, except 2 studies that relied on self-reported histories.21,22
Quality
The method quality of included studies was good (n = 3), fair (n = 6), and poor (n = 1). The 
most common validity threats were noted in measurement and interpretation of results. 
Specifically, 6 studies did not report evidence that exposure measures were valid.12,15,19-22 
Additionally, 4 studies did not specifically exclude women with CVD before 
pregnancy,12,19,20,22 and all but 2 studies failed to adjust for smoking, which is an important 
potential confounder.14,21 All studies adjusted for, or otherwise controlled for, age and 
hypertension/preeclampsia; 7 studies adjusted for socioeconomic status (SES)12,14-16,19-21; 5 
studies adjusted for birthweight/fetal growth restriction,15,16,18-20 and 2 studies examined 
interactions with birthweight.14,17
Findings
CVD morbidity—Two fair-quality studies reported positive associations with CVD 
morbidity: a US based cross-sectional study21 and a cohort study conducted in Denmark15 
(Tables 2 and 3). The US study was based on a subsample of women who lived in Pittsburgh 
(n = 446) and who had participated in a large cohort epidemiologic study called The Study 
of Health, Aging, and Body Composition. This subsample had an average age of 80 years; 
47% of the participants were black. Overall, women who self-reported history of PTB had 
an adjusted odds ratio of 2.9 (95% confidence interval [CI], 1.2–6.9) for self-reported CVD 
incident events that occurred from 1998-2002.22 That study did not exclude women with 
heart disease before first delivery. The other study (n = 427,765) included all Danish women 
with deliveries that occurred from 1973-2006 and also reported excess risk that was 
associated with a history of PTB for CVD among women without previous CVD (adjusted 
hazard ratio [aHR], 1.2; 95% CI, 1.1–1.3). Registry data were used for that study with 
follow-up time that ranged from 23–33 years (mean, 28 years).15
IHD morbidity—We reviewed 2 studies that examined IHD morbidity (Tables 2 and 
3).14,17 The fair-quality cohort study that was conducted in Denmark and investigated the 
association of PTB and CVD also reported a statistically significant association for IHD 
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morbidity (aHR, 1.4; 95% CI, 1.3–1.5).15 An even larger, good-quality cohort study 
(1978-2007; n = 782,287) followed Danish women with singleton deliveries for 15 years 
(median). Those investigators conducted stratified analyses by degree of preterm, 
controlling for age, year of delivery, and several adverse pregnancy outcomes. They 
reported a 60% increased risk of IHD (95% CI, 1.1e2.4) for the most severe PTB (20-27 
weeks’ gestation), no statistically significant association for PTB at 28-31 weeks’ gestation, 
and 30% increased risk for PTB at 32-36 weeks’ gestation (95% CI, 1.2e1.6).18
CVD/IHD death—Women with a history of PTB had approximately twice the risk of CVD 
or IHD-related death as women with term births (Figure 2; Table 1).12,15-17,20 A poor-
quality study reported a similar association (aHR, 2.1; 95% CI, 1.2e3.5) based on 35 years 
of follow up (mean) on a Finnish sample of 3706 women with PTB and singleton deliveries 
documented in their Helsinki maternity records between 1954 and 1963.12 Four fair- or 
good-quality cohort studies reported similar levels of risk (aHR range, 1.9–2.2),15-17,20 
although the association (aHR, 1.9; 95% CI, 0.7–4.9) was not statistically significant in 1 
study.20 The nonsignificant findig was reported in a fair quality study that included 129,920 
women with singleton first births in Scotland between 1981 and 1985 (follow up ranged 
from 15–19 years).20 In the previously mentioned Danish study that investigated numerous 
morbidity outcomes (fair quality; n = 427,765), Catov et al15 followed women for 28 years 
(mean) and reported that women with PTB had excess CVD death compared with women 
with term deliveries (aHR, 2.0; 95% CI, 1.7–2.3). Another Danish study (n = 782,287) 
included women from 15-50 years old with a first, singleton delivery from January 1978 to 
October 2007 (median follow up time, 15 years) and reported an increased risk of CVD 
death that was associated with history of PTB (aHR, 2.0; 95% CI, 1.6–2.4).17 A large fair-
quality cohort study (n = 551,488) of all women with first singleton live births from January 
1969 to July 2007 in Scotland reported a positive association of any PTB and subsequent 
maternal death from IHD (aHR, 2.3; 95% CI, 1.9e2.7).16 Registry data were used for that 
study with a mean follow-up period of 22 years.
IHD hospitalization or death (combined)—Three fair-quality studies reported excess 
risk associated with a history of PTB and subsequent maternal hospitalizations or death that 
was related to IHD (Table 3).16,20,21 The previously mentioned Scottish study on IHD death 
outcomes (n = 129,920) also investigated the association of PTB (24-36 weeks’ gestation 
inclusive) with any IHD event (ie, death or hospital admission because of IHD) and reported 
increased risk (aHR, 1.8; 95% CI, 1.3e2.5).20 A nested case-control study (n = 504) reported 
a positive association between PTB and subsequent diagnosis of or death from IHD (aHR, 
2.1; 95% CI, 1.1e4.1).21 That fair-quality study was based on a subsample from a French 
prospective cohort study that investigated cancer risk factors in 98,997 women who 
belonged to a major health insurer of teachers and who were born from 1925-1950.21 
Control subjects were matched to medically verified cases on birth year, cohort study 
enrollment date, education, and residence. A history of PTB was self-reported for births that 
had occurred from 42-68 years earlier and were defined as delivery at ≤8 months’ gestation. 
Self-reported IHD was validated with medical records. The large study (n = 551,488) that 
was conducted in Scotland that investigated the association of PTB and IHD death also 
reported an association for PTB and any IHD event (fatal or nonfatal; aHR, 1.6; 95% CI, 
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1.5–1.7).16 Those investigators separately analyzed the data, stratifying PTB by spontaneous 
(defined as vaginal delivery without induction or cesarean delivery after onset of labor) and 
elective (ie, induced delivery without onset of labor). Compared with term births, 
associations for elective PTB (aHR, 1.8; 95% CI, 1.6–2.0) were greater than associations 
between spontaneous PTB and IHD death (aHR, 1.5; 95% CI, 1.3–1.6; P = .005).
CVD/cerebrovascular disease hospitalization or death (combined)—Two studies 
reported excess risk associated with a history of PTB and subsequent maternal 
hospitalizations or death from CVD or cerebrovascular disease (Table 3).14,19 A fair-quality 
Scottish study reported excess risk associated with a history of PTB (24-36 weeks’ gestation 
inclusive) and subsequent maternal hospitalizations or death (combined) from 
cerebrovascular disease only.19 Those researchers used vital records data from 119,668 
women with deliveries (1981- 1985). They controlled for confounding by SES and 
preeclampsia and examined interactions with birthweight. They reported an increased risk of 
1.9 (95% CI, 1.4–2.7) but no evidence of interaction. In a good-quality study, Bonamy et 
al14 used vital records data from 923,686 women with first singleton births in Sweden from 
1983-2005 and observed them through December 2005 (median, 12 years) to assess risk of 
first occurrence of maternal hospitalization or death from IHD stroke or heart failure. In 
addition to controlling confounding from SES, they also adjusted for hypertension, 
preeclampsia, diabetes mellitus, and smoking and examined interactions with birthweight. 
Compared with mothers of term infants with normal weight for gestational age, those 
investigators reported increased risk of subsequent CVD for mothers who delivered infants 
at ≤27 weeks’ (aHR, 2.2; 95% CI, 1.3–3.6), 28-31 weeks’ (aHR, 2.6; 95% CI, 2.0–3.3), and 
32-36 weeks’ gestation (aHR, 1.4; 95% CI, 1.2–1.6).14
Associations with recurrent PTBs—Two Danish studies (1 fair- and 1 goodquality) 
examined the associations of recurrent PTBs and CVD outcomes (Table 5).15,18 The fair-
quality cohort study is the same one that also investigated the association of PTB and CVD, 
IHD, stroke, atherosclerosis, and CVD death.15 For their analysis of the association between 
recurrent PTB and CVD, Catov et al15 used a subsample of women with ≥2 births (n = 
182,146) and compared those with only term births to women with ≥1 PTBs. Among 
women with 1 PTB (aHR, 2.7; 95% CI, 1.7–4.4) and with ≥2 PTBs (aHR, 8.7; 95% CI, 4.4–
17.3), the strongest association was with atherosclerosis. As seen with atherosclerosis, the 
risk of IHD was higher among women with ≥2 PTBs (aHR, 1.8; 95% CI, 1.4–2.3) compared 
with women who had ≥2 births but only 1 PTB (aHR, 1.2; 95% CI, 1.1–1.4). Confidence 
intervals for risk estimates of CVD, stroke, and CVD death by recurrent PTB status (only 1 
vs ≥2 PTBs) overlapped. The 2 studies reported 1.4-1.8 times increased risk of IHD among 
women with ≥2 PTBs.15,18 Investigators from those 2 studies also examined CVD risk by 
timing of PTB among a subsample of women who had ≥2 births but ≥1 PTB, and no clear 
pattern was evident.15,18
Comment
This systematic review provides a comprehensive overview of the current state of research 
examining CVD risk in mothers who have histories of PTB. Metaanalysis was not 
performed and can be misleading when observational studies are used because of 
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heterogeneity of available studies.23 All included studies found that having a PTB was 
associated with a statistically significant increase in future CVD. The results were 
consistent, despite the fact that these studies examined a variety of CVD outcomes and 
included morbidity or death or both. The 2 studies that examined CVD risk among women 
with ≥2 births reported higher risks among subsamples with ≥2 PTBs compared with women 
who had only 1 PTB.
Elucidating the strengths and weaknesses of the included studies is important for translation 
of the evidence from this review. All but 2 studies linked data from large registries that 
enabled population level analyses and minimized selection bias.21,22 Sample sizes of the 
individual studies ranged from 446e 923,686. Unmeasured risk factors that were associated 
with PTB and with CVD in the mother may confound observed associations if they are not 
adjusted for in the analyses. However, most studies adjusted for or examined interactions 
with hypertension/preeclampsia, birth- weight, and SES. Smoking was left unmeasured in 8 
studies, possibly resulting in overestimated associations. In the 2 studies that controlled for 
smoking, the adjustment had no influence on the associations.14,21 For the outcome of IHD 
hospitalization or death, the association remained even after adjustment for smoking21 and 
was similar in magnitude to 3 other studies that did not control for smoking.16,20,21 Only 
one-half of the studies excluded women with CVD before the first birth in the study 
period,14,15,17,18,21 yet, estimates of risk in those studies were comparable with estimates 
from studies that did not have this exclusion criterion. All but one study focused 
predominantly on white populations; thus, whether associations are consistent across other 
racial and ethnic groups remains unknown.22 Finally, we acknowledge the possibility of a 
cardioprotective effect for term pregnancy, rather than risk because of PTB.24
This review has several strengths that include manual review of reference lists for the 
identification of relevant studies, a report of study flow that detailed the selection of studies, 
and geographic breadth of studies that spanned the globe. Additionally, we used a quality 
assessment instrument that is based on methods that were used in other systematic reviews. 
Although that instrument offers flexibility for evaluation of articles with different study 
designs, it is intended as a measure of how well the selected study design was executed. 
Therefore, the type of study design was not weighted in the quality assessments. Despite our 
efforts to thoroughly and fairly evaluate the evidence, the possibility of publication bias and 
exclusion of reports in non-English language may have led to the exclusion of relevant 
studies. Given that this systematic review included studies that were published over a time 
span of 17 years and that we identified only 10 relevant articles, the amount of literature that 
examined this research question is relatively small. Moreover, we found major overlap in 2 
articles,19,20 and we found minor overlap in 2 articles that used the same datasets.17,18
CVD is a result of a complex interplay of multiple factors that span the life course, and some 
of the many pathways that lead to PTB may share common physiologic processes with 
CVD. Although the pathophysiologic processes that are responsible for the consistently 
reported associations between a history of PTB and subsequent CVD are uncertain, common 
inflammatory processes and genetic determinants have been posited as possible mechanisms 
of action for both.11,25 Levels of risk were particularly high for atherosclerosis, which may 
provide insight into underlying mechanisms and support etiologic hypotheses of 
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inflammatory processes.11,26 Inflammation may also play a key role in the explanation of 
the pathophysiologic process underlying the association between preeclampsia and future 
CVD.5-7,27 Although preeclampsia can lead to PTB, all studies that were included in the 
review adjusted for or excluded pregnancies that were complicated by preeclampsia and 
gestational hypertension. Thus, our results suggest that the association between PTB and 
future CVD is independent of hypertensive disorders in pregnancy. In fact, emerging 
evidence supports our thinking. A 2013 study reported a linear association between the 
number of previous PTBs and a risk of future CVD hospitalization.28
Studies rarely account for the heterogeneity that is inherent in the PTB syndrome.29 For 
example, only one study differentiated between spontaneous and indicated PTB. Most PTBs 
occur as a result of spontaneous onset of labor and/ or rupture of fetal membranes before 
term,9 and there are likely inflammatory, vascular, and/or neuroendocrine pathways 
involved in these births. The current literature cannot distinguish among these pathways, and 
the degree to which specific pathophysiologic spontaneous preterm labor presentations 
might be associated with subsequent CVD cannot be determined.9 However, the associations 
for both types of PTB with CVD are biologically plausible. The leading causes for indicated 
PTB are hypertensive disorders in pregnancy, which include preeclampsia and/or 
intrauterine growth retardation, although spontaneous PTB may be initiated by multiple 
factors.9 Nevertheless, increased systemic inflammation, increasing stimulation of the 
infection or inflammation pathways,30 and oxidative stress, which are well-known 
promoters of atherogenesis, also have been reported to be present in preeclampsia, fetal 
growth restriction, and spontaneous preterm labor.31 It remains to be determined whether the 
associations of these pregnancy complications and CVD are due to pregnancy acting as a 
stress test that exposes a predilection for antiinflammatory and antioxidative dysfunction or 
whether these complications cause long-lasting subclinical damage to these 
antiatherosclerotic mechanisms that later contribute to the development of CVD.
Despite comparability and measurement challenges, nearly all included studies reported 
statistically increased risk of CVD outcomes that are associated with PTB. Although the 
magnitude of the risk may be modest, on a population level, PTB can identify a nontrivial 
number of women who are at increased risk of CVD (approximately one-half million 
women each year in the United States). Because most cardiac sudden deaths in women occur 
in the absence of a previous diagnosis of heart disease,32,33 having comprehensive 
information about a woman’s risk profile, which would include a history of reproductive 
health outcomes, enables optimal risk-appropriate screening, monitoring, and treatment. 
Delivery of a preterm infant may be the first indication that a woman has increased risk of 
the development of CVD. The American Heart Association’s 2011 update on effectiveness-
based guidelines for CVD prevention in women suggests that women with a history of 
gestational diabetes mellitus, hypertensive disorder in pregnancy, PTB, and/or delivery of a 
small-for-gestationalage infant may benefit from having their CVD risk factors carefully 
monitored.2
The current systematic review confirms that a history of PTB is an important CVD risk 
factor that is unique to women. Additional high-quality, longitudinal studies of racially and 
ethnically heterogeneous younger age women are needed to augment this systematic review. 
Robbins et al. Page 8
Am J Obstet Gynecol. Author manuscript; available in PMC 2015 April 07.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Positive findings from such studies may tilt the weight of evidence toward institutionalized 
incorporation of PTB into CVD risk calculation in women. Given the accumulating evidence 
for such an association, clinicians may consider educating women about their increased risk, 
because this could motivate women to control their modiflable risk factors. Future research 
is needed to understand the potential impact of enhanced monitoring of CVD risk factors in 
women with a history of PTB on the risk of future CVD.
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FIGURE 1. 
Flow chart illustrates the selection of individual studies
Selection of studies that examined the association of preterm birth and/or fetal growth 
restriction with cardiovascular disease.
Robbins. Preterm birth and cardiovascular disease. Am J Obstet Gynecol 2014.
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FIGURE 2. 
Association of PTB and subsequent maternal death from CVD or IHD
Graph depicts the association.
CVD, cardiovascular disease; IHD, ischemic heart disease; PTB, preterm birth.
Robbins. Preterm birth and cardiovascular disease. Am J Obstet Gynecol 2014.
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TABLE 1
PubMed/MEDLINE search strategy
All fields and title abstract Topica
Predictors Fetal growth restriction
Fetal growth retardation
Low birthweight
Low birthweight infant
Small for gestational age
Very low birthweight infant
Extremely low birthweight infant
Intrauterine growth restriction
Intrauterine growth retardation
Premature infant
Prematurity
Premature birth
Birthweight
Newborn
Preterm delivery
Pre-term delivery
Newborn infant
Complicated pregnancies
Pregnancy complications
Preterm birth
Adverse pregnancy events
Cardiovascular-related outcomes Cardiovascular disease
Cardiovascular pregnancy complications
Hypertension
Dyslipidemia
Hypercholesterolemia
LDL cholesterol
HDL cholesterol
High blood pressure
Hyperlipemia
Hyperlipidemia
Lipemia
Lipidemia
Lipid disorders
Cholesterol
Low density lipoprotein cholesterol
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All fields and title abstract Topica
High density lipoprotein cholesterol
Triglycerides
Cerebrovascular accident
Cerebrovascular disease
Ischemic heart disease
Ischaemic heart disease
Myocardial ischemia
Myocardial ischaemia
Thromboembolism
Coronary heart disease
Arteriosclerosis
Cardiovascular death
Cardiovascular morbidity
Cardiovascular risk factors
Cardiovascular risk
Vascular risk
Morbidity and death-related outcomes Mortality
Death
Cause of death
Fatal outcome
Survival rate
Premature death
Hospital death
Maternal death
Maternal risk
Mothers’ risk
Death risk
Death of mothers
LDL, low-density lipoproteins.
aAlso entered as MeSH database terms.
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TABLE 2
Individual preterm birth studies
Study Study design/country Eligible population and 
description of sample
Assessment of 
gestational age
Assessment of outcome
Smith et 
al,
200012
Cohort study/Finland Women with live, singleton births 
from 1954-1963
in Helsinki; analytic sample, 3706 
women
Preterm: <37 
weeks’ gestation;
source: Helsinki 
maternity
care records
Cardiovascular disease death; source:
Finnish central population and cause-
of-death
registers
Smith et 
al,
200120
Cohort study/Scotland Women with singleton first births in 
Scotland from
1981-1985 (n = 137,094); 
exclusions: stillbirths,
infants born alive at <24 weeks’ 
gestation and those
with birthweight <500 g, women 
with previous
pregnancies; analytic sample, 
129,920 women (94.8%)
Based on estimated 
date of delivery;
preterm: 24-36 
weeks’ gestation;
source: Scottish 
Morbidity
Record System
Death because of ischemic heart disease 
or any
ischemic heart disease hospitalization 
or death
per ICD-9 or 10 codes; source: Scottish 
Morbidity
Record System
Pell et al,
200419
Cohort/Scotland Women with singleton first births in 
Scotland from
1981-1985 (n = 137,094 women); 
exclusions:
stillbirths, infants born alive at <24 
weeks’ gestation
and those with birthweight <500 g, 
women with
previous pregnancies; analytic 
sample = 119,668
(87.3%)
Based on estimated 
date of delivery;
preterm: 24-and 36 
weeks’ gestation;
source: Scottish 
Morbidity
Record System
Death or hospital admission because of 
a principal
diagnosis of stroke (ischemic stroke, 
intracranial
hemorrhage, or transient ischemic 
attack) per
ICD-9 codes; source: Scottish 
Morbidity
Record System
Nardi et 
al,
200621
Retrospective nested
case control study from
the E3N study
cohort/France
Cases were women born 1925-1950 
who self-reported
having had a first myocardial 
infarction from 1990-
2000 and had a singleton live birth (n 
= 144);
exclusions: previous cardiovascular 
problems,
psychiatric disorders, and other 
noncardiac diseases;
analytic sample = 504 women: 109 
cases (75.7%),
and 395 randomly selected control 
subjects matched
on birth year, month/year of E3N 
enrollment,
education, and residence area
Preterm: self-
reported length
of pregnancy at ≥8 
months;
source: survey
Self-reported ischemic heart disease; 
source:
survey responses validated by review of 
hospital
discharge records or death because of 
ischemic
heart disease per ICD-9 code
Catov et 
al,
200722
Cross-sectional study
(the study of health,
aging and body
composition -health
ABC)/Pittsburgh, PA
Women 70-79 years old in 
1997-1998 who reported
having had ≥1 live birth, were well-
functioning, had
ongoing plans for community-
dwelling (n = 507
women); exclusion: women who did 
not provide
pregnancy history details at the 
interview; analytic
sample = 446 (88.0%)
Preterm: self-
reported length
of pregnancy at 
<37 weeks;
source: survey
Self-reported cardiovascular disease: 
ischemic
heart disease, stroke; or peripheral 
vascular disease;
ischemic heart disease included 
myocardial infarction,
angina, coronary artery bypass surgery, 
or
percutaneous transluminal angioplasty; 
source:
survey responses validated by 
medications and
electrocardiogram results
Catov et 
al,
201015
Cohort
study/Denmark
Women with no previous 
cardiovascular disease or
diabetes mellitus diagnoses who 
delivered a singleton
live or still birth in Denmark from 
1973-1983 (n =
Based on last 
menstrual period;
preterm: <37 
weeks’ gestation;
categorized as: 
≥32, 33-34,
Composite endpoint per ICD-8 or 
ICD-10 code was first
cardiovascular disease outpatient visit, 
hospitalization,
or death (because of atherosclerosis; 
hypertensive
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Study Study design/country Eligible population and 
description of sample
Assessment of 
gestational age
Assessment of outcome
453,337); exclusions: children who 
were adopted or
could not be matched to mothers, 
women with missing
information related to gestational 
age, previous
hospitalization for cardiovascular 
disease or diabetes
mellitus, death during delivery, 
missing information on
education; analytic sample = 427, 
765 (94.4%);
analytic subsample of women with 
≥2 births =
182,146
or 35-36 weeks’ 
gestation; source:
the Danish Medical 
Birth Registry
disease; ischemic heart disease; stroke; 
and
thrombosis); ischemic heart disease, 
stroke,
hypertension, atherosclerosis, or 
thrombosis
examined separately; source: the 
National Hospital
Discharge Register
Lykke et 
al,
201018
National registry-based
cohort study/Denmark
Women 15-50 years old with no 
previous
cardiovascular or diabetes mellitus 
diagnoses who
delivered a first singleton in 
Denmark from January
1978 to October 2007 (n = 796,915); 
exclusions:
women with previous cardiovascular 
or diabetes
mellitus diagnoses and those who 
died or emigrated
within 3 months of delivery; analytic 
sample for cohort
1 = 782,287 (98.2%); cohort 2 = 
subpopulation of
cohort 1, defined as women who had 
a first delivery
at >15 years old and second 
singleton delivery
at <50 years old (n = 550,809); 
exclusions: women
with cardiovascular or diabetes 
mellitus diagnoses
before the second delivery and those 
who died or
emigrated within 3 months of the 
second delivery
Analytic sample for cohort 2 = 
536,419 (97.4%)
Preterm: <37 
weeks’ gestation;
categorized as: 
20-27, 28-31,
or 32-36 weeks’ 
gestation; source:
the National 
Patient Registry
First diagnosis of ischemic heart 
disease per ICD-8 and
10 codes; source: linked data from the 
National Patient
Registry, the Danish Central Person 
Registry, and the
Cause of Death Registry
Lykke et 
al,
201017
National cohort
study/Denmark
See description for cohort 1 18 Preterm: <37 
weeks’ gestation;
source: National 
Patient Registry
Death from any cardiovascular disease 
per ICD-8
or 10 codes or a first cardiovascular 
disease diagnosis
reported at ≤1 week before death 
(caused by any
cardiovascular disease, hypertensive 
disease;
ischemic heart disease; myocardial 
diseases, stroke;
and thromboembolic diseases, or type 2 
diabetes
mellitus); sources: linked data from the 
National
Patient Registry, the Danish Central 
Person Registry,
and the Cause of Death Registry
Bonamy 
et al,
201114
National cohort
study/Sweden
Resident women with a first 
singleton birth in Sweden
from 1983-2005 and no previous 
cardiovascular
event (n = 957,412); exclusions: 
missing information
on birthweight or gestational age or 
missing record in
Term: ≥37 weeks’ 
gestation;
moderately 
preterm:
32-36 weeks’ 
gestation; very
preterm: 28-31 
weeks’ gestation;
Cardiovascular disease incidence or 
death (defined as
primary diagnosis for first 
hospitalization or underlying
cause of death caused by coronary heart 
disease,
unstable angina or acute myocardial 
infarction), stroke
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Study Study design/country Eligible population and 
description of sample
Assessment of 
gestational age
Assessment of outcome
the medical birth register; analytic 
sample = 923,686
(96.5%)
extremely preterm: 
≤27 weeks’
gestation; source: 
ultrasound scan
or last menstrual 
period
(cerebral infarction, cerebral 
hemorrhage,
subarachnoid hemorrhage, transient 
ischemic attack,
or other acute stroke), or heart failure 
per ICD-8 and
9 codes; sources: the Hospital 
Discharge Register,
the Cause of Death Registry
Hastie et 
al,
201116
Cohort
study/Scotland
Women with first singleton live-
births from January
1969 to July 2007 and 35-65 years 
old at the time
of their first ischemic heart disease 
event or at the
end of follow-up (n = 750,350); 
exclusions: women
with maternal age at delivery of <12 
years,
birthweight <500 g, and gestational 
age <24 weeks
or >43 weeks; analytic sample = 
551,488 (73.5%)
Preterm: <37 
weeks’ gestation;
term: ≥37 weeks’ 
gestation;
mild-moderate 
preterm:33-36 
weeks’
gestation; extreme 
preterm:
24-32 weeks’ 
gestation; source:
Scottish Morbidity 
Record System
Ischemic heart disease death or event 
per ICD-8,
ICD-9, or ICD-10 code; source: linked 
data from
the Scottish Morbidity Records and 
Scotland’s
Registrar General
ICD, International Classification of Diseases, 8th, 9th, or 10th revision.
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TABLE 4
Definitions of outcomes used in individual studies
Source code
Reference Definition details ICD-7 ICD-8 ICD-9 ICD-10 Other
Atherosclerosis
 Catov et al, 201015 Atherosclerosis hospitalization or 
death
440 170-170.9
Cerebrovascular disease
 Pell et al, 200419 Stroke hospitalization or death 430-438 160-169, G45
 Catov et al, 201015 Stroke hospitalization or death 430-438 160-169.8
Cardiovascular disease
 Smith et al, 20012 Cardiovascular disease deaths Not specified
 Catov et al, 200722 Cardiovascular disease morbidity: 
myocardial
infarction, stroke, peripheral vascular 
disease,
angina, coronary artery bypass 
surgery, or
percutaneous transluminal 
angioplasty
Self-reported and 
validated
with algorithms that 
included
selected medications 
and
electrocardiogram
 Catov et al, 201015 Cardiovascular disease outpatient 
visit, hospitalization,
or cardiovascular disease deaths from 
atherosclerosis;
hypertensive disease; ischemic heart 
disease; stroke;
and thrombosis; NOTE: ischemic 
heart disease, stroke,
hypertension, atherosclerosis, or 
thrombosis also
examined separately
390-459 100-199
 Bonamy et al, 201114 Cardiovascular disease deaths or 
hospitalizations:
coronary heart disease, stroke, or 
heart failure
410, 411, 
430-436,
427, 
427.10
410, 
411B,
430-436, 
428
120.0, 
121-122, G45,
1160-1164, 
150
 Lykke et al, 201017 Cardiovascular disease deaths: any 
cardiovascular
disease or ischemic heart disease, 
stroke, myocardial
infarction, hypertension, 
thromboembolic disease,
or type 2 diabetes mellitus
Ischemic heart disease
 Smith et al, 200120 Ischemic heart disease hospitalization 
or death
410-414 120-125
 Nardi et al, 200621 Myocardial infarction Self-reported and 
validated with
information on 
diagnosis, ECC, and
Am J Obstet Gynecol. Author manuscript; available in PMC 2015 April 07.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Robbins et al. Page 22
Source code
Reference Definition details ICD-7 ICD-8 ICD-9 ICD-10 Other
enzymatic dosages 
via interviews
with general 
practitioners and
review of hospital 
and ischemic
heart disease death 
records
 Catov et al, 201015 Ischemic heart disease hospitalization 
or death
410-414 120-125.5
 Lykke et al, 201018 Ischemic heart disease hospitalization 410-414 120-125
 Hastie et al, 201116 Ischemic heart disease hospitalization 
or death
410-414 410-414 120-125
ECC, electrocardiogram; ICD, International Classification of Diseases, 7th, 8th, 9th, or 10th revision.
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TABLE 5
Studies that examined associations between PTB and CVD outcomes, stratified by the number of PTBs
1 PTB ≥2 PTBs
Study Sample, na Outcome Adjusted hazard ratio 95% CI Adjust hazard ratio 95% CI
Catov et al, 201015, b 182,146 Cardiovascular disease 1.2 1.1–1.3 1.4 1.2–1.6
Ischemic heart disease 1.2 1.1–1.4 1.8 1.4–2.3
Stroke 1.8 1.4-2.2 1.4 0.8-2.5
Atherosclerosis 2.7 1.7–4.4 8.7 4.4–17.3
Cardiovascular disease death 1.7 1.3–2.2 2.1 1.2–3.7
Lykke et al, 201018, c 536,419 Ischemic heart disease 1.1d 0.9–1.2 1.4 1.0–1.8
1.2e 1.0–1.4
CI, confidence interval; CVD, cardiovascular disease; PTB, preterm birth.
aSample limited to women with ≥2 singleton births in the study period;
bAdjusted for age, socioeconomic status, parity, education;
cAdjusted for age, year of delivery, hypertensive pregnancy disorders, small or large for gestational age, placental abruption, stillbirth;
d
PTB in first pregnancy;
e
PTB in second pregnancy.
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